Value proposition

Unlocking the matrix barrier to treat fibrotic diseases

TANDEM Therapeutics is a discovery stage Swiss biopharmaceutical company bringing a novel precision targeting approaches to fibrosis and fibrotic cancers. We advance over 15 years of transformative research and development at ETH Zürich and Paul Scherrer Institut in the field of extracellular matrix biology and the critical role it plays in the pathology of fibrotic cancers & organ fibrosis. The therapeutic platform is based on Matrix Targeting Peptides (MTP) that conditionally target disease associated matrix alterations that are known to be directly associated with several fibrotic diseases.